University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Grand Rounds > Pediatric HIV Treatment > Slides
Current Issues in Pediatric HIV Treatment
Slide 1.
Current Issues in Pediatric HIV Treatment
Slide 1.
Outline
Slide 2.
Case 1
Slide 3.
Current DHHS Guidelines
Slide 4.
HPTN 040:Infants of Mothers with No ARV During Pregnancy (other than ZDV in labor)
Slide 5.
HPTN 040:Infants born to Mothers with No ARV During Pregnancy (other than ZDV in labor)
Slide 6.
HPTN 040:Infants born to Mothers with No ARV During Pregnancy (other than ZDV in labor)
Slide 7.
Table 4: Viral Resistance According to Treatment Group
Slide 8.
Improving on HPTN 040
Slide 9.
Optimal Treatment of the in Utero Infected Infant
Slide 10.
The Mississippi Infant
Slide 11.
The Mississippi Infant
Slide 12.
Viral Decay Over First 100 Days
Slide 13.
The Mississippi Infant
Slide 14.
Update on The Mississippi Infant
Slide 15.
How Did This Change The Field?
Slide 16.
Prophylaxis vs the Mississippi Protocol
Slide 17.
Target Serum Levels of NVP Differ for Prophylaxis vs Treatment
Slide 18.
Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study (IMPAACT P1115)
Slide 19.
Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study (IMPAACT P1115)
Slide 20.
The Very Early Treatment Cohort
Slide 21.
Case 1 (cont)
Slide 22.
Case 1 (cont)
Slide 	23.
What about Other ARVs
Slide 24.
Other ARVs for Neonatal Treatment?
Slide 25.
What about LPV/r?
Slide 26.
Slide 27
Slide 27.
Slide 28
Slide 28.
Promise- DSMB Stopped Phase 1
Slide 29.
Current State of HIV Prophylaxis for Infants
Slide 30.
Case 2
Slide 31.
Pediatric vs Adult Data
Slide 32.
LPV/r vs NVP for Infants (p1060)
Slide 33.
LPV/r vs NVP for Infants (p1060)
Slide 34.
Promote Peds
Slide 35.
Best First Line ART for < 3 Years Old?
Slide 36.
Odyssey (PENTA 20)
Slide 37.
Thinking Ahead: Older Children
Slide 38.
Young Adults in the USA
Slide 39.
Rates of Diagnosis of HIV Infection among Adults and Adolescents, 2012 - United States and 6 Dependent Areas
Slide 40.
Rates of Diagnosis of HIV Infection among Adolescents Aged 13-19 Years, 2011 - United States and 6 Dependent Areas
Slide 41.
Rates of Diagnosis of HIV Infection among Young Adults Aged 20-24 Years, 2011 - United States and 6 Dependent Areas
Slide 42.
Stage 3 (AIDS) Classifications among Young Adults Aged 20-24 Years, by Sex, 1985-2011 - United States and 6 Dependent Areas
Slide 43.
Diagnoses of HIV Infection and Population among Young Adults Aged 20-24 Years, by Race/Ethnicity 2011- United States
Slide 44.
Diagnoses of HIV Infection among Adolescent and Young Adults Males, by Age Group and Transmission Category 2011 - United States and 6 Dependent Areas
Slide 45.
Diagnoses of HIV Infection among Adolescent and Young Adults Females, by Age Group and Transmission Category 2011 - United States and 6 Dependent Areas
Slide 46.
SFGH Youth
Slide 47.
Bay Positives
Slide 48.

We request that all users complete the brief posttest and evaluation to provide feedback to course planners and presenters. Those requesting CME credit are required to complete all components to receive credit. Begin with the posttest.